|
|
 |
|
Viewing report
|
|
|
|
Respiratory Syncytial Virus: High Incidence + Few Interventions = Large Market Opportunity
Decision Resources, Inc., March 2010, Pages: 32
Sales of the only effective agent for respiratory syncytial virus (RSV) hit the billion-dollar mark in 2005, seven years after launch, and continue to grow steadily. Elderly patients—whose event rates will increase by up to 33% in the next ten years—and infants need an effective antiviral or vaccine. With few competitors and great unmet need, this market is primed for competitive entry. As one physician we interviewed says, “RSV will be like influenza once you have a treatment. We see far more RSV in children than we do influenza in children.” Further, adults and the elderly are rarely diagnosed with RSV—although they certainly experience the disease. This group of patients should be of particular interest to drug developers.
Questions Answered in this Report
- Approximately 95% of children are infected with RSV by the time they are two years old. How many cases do Decision Resources epidemiologists forecast in the major pharmaceutical markets over 2008-2018? What types of RSV-related diseases will high-risk children contract, and how will they be treated? How are they diagnosed and by whom?
- Approximately 170,000 hospitalizations and 10,000 deaths occur among the elderly (older than age 64) every year from RSV-related disease. How are diagnosis and treatment of immunocompromised adults and the elderly different from those of pediatric patients? What are some of the challenges in diagnosing and treating these populations? How many cases of RSV in all age-groups are underdiagnosed or misdiagnosed?
- Only one prophylactic and one treatment are available on the market for serious cases of RSV in pediatric patients, and none are available for adults. MedImmune’s motavizumab is slated to launch in 2010 for high-risk infants. But why have more drugs not been developed? What are the most promising therapy areas being investigated? What companies have been most active in drug development?
Scope
- Current market and outlook: 2009-2014 drug sales, historical and current therapies, market-leading companies, commercial position of leading agents, potential of emerging agents.
- Epidemiology: pediatric and elderly event cases and event rates from 2008 to 2018.
- Primary research: expertise and clinical knowledge from U.S. key opinion leaders weighing in on current and emerging therapies as well as their own prescribing practices.
- Pipeline analysis: emerging therapies and vaccines, innovative technology, different opportunities for different age-groups, unmet needs, MedImmune (AstraZeneca) (motavizumab, MEDI-557, MEDI-559, MEDI-534).
- Opportunities in treating RSV: need for greater disease awareness; misdiagnosis and underdiagnosis in certain patient groups; cost-prohibitive therapies; lack of new therapies or therapies for adults; lack of urgency in the healthcare community.
Keywords:
Antivirals, Blockbuster drugs, Drug costs, Drug development strategy, Geriatric disease, Immunoprophylaxis, Infectious disease, Pediatric disease, Respiratory disease, Respiratory syncytial virus, RSV, Synagis, Vaccines, Viral disease, Virus
Customers who bought this item also bought
Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
Respiratory Syncytial Virus (Rsv) Infection - Pipeline Review, Q3 2011
Antivirals: Novel Targets, Technologies, and Dealmaking
Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019
Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent Market Developments
The Antivirals Pipeline: Competitive Review
Competitor Analysis: RSV Vaccines and Therapeutics
Pricing and Reimbursement of Antivirals
Human Vaccines - Global Strategic Business Report
Antivirals - Global Strategic Business Report
|
|
|
|
